

HEPATITIS B COUNTRY PROFILE

SRI LANKA


| Country Demographics ^{1,2,3,6} | |
|---|------------|
| Total population (2020) ⁶ | 22,889,201 |
| Urban population (% of total, 2020) ⁶ | 18.7% |
| Health expenditure per capita (\$US, 2017) ² | \$159.48 |
| Health expenditure, total (% of GDP, 2017) ² | 3.81% |
| Total births in thousands (2018) ³ | 308 |
| Surviving infants in thousands (2018) ³ | 306 |
| Life expectancy at birth (years, 2020) ⁶ | 77.5 yrs |
| Number of districts (2013) ¹ | 26 |

| HBsAg Prevalence ⁵ | |
|-------------------------------|-------|
| Pre-vaccine HBsAG+ (%) | 2.51% |

| Liver Cancer as Cause of Cancer Death (in Men) ⁴ | |
|---|-------------|
| Year: 2022 | Ranking: 11 |

| 2023 Country Comparison in South East Asia Region (11 Countries) ³ | | | | |
|---|-----------|--|-----------------------------------|---|
| | Sri Lanka | Number of countries with reported coverage | Highest reported coverage in SEAR | Lowest reported coverage in SEAR |
| HepB3 ³ | 99% | 11 | 99% (Bhutan, Maldives, Sri Lanka) | 16% (Democratic People's Republic of Korea) |
| HepB BD ³ | NR | 8 | 99% (Maldives) | 0% (Democratic People's Republic of Korea) |

| Hepatitis B Immunization Coverage ³ | | | | | | | | | | | | | | | | | | | | | | | | |
|--|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| HepB3 ³ | NR | NR | NR | 32% | 62% | 99% | 98% | 98% | 98% | 97% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 96% | 96% | 98% | 99% |
| HepB BD ³ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| DTP3 ³ | 99% | 98% | 98% | 99% | 97% | 99% | 98% | 98% | 98% | 97% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 96% | 96% | 98% | 99% |
| BCG ³ | 98% | 98% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% | 99% |



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. WHO UNICEF: Immunization Summary: A statistical reference containing data through 2013¹, World DataBank: World Development Indicators database², WHO Vaccine-Preventable Diseases: Monitoring System. <https://data.unicef.org/resources/dataset/immunization/> accessed 01/09/2025.³, Global Cancer Observatory: Cancer Toda-IARC⁴, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013⁵, CIA The World Factbook⁶